tetano
Editor, Senior Moderator
J Virol
. 2020 Nov 11;JVI.02154-20.
doi: 10.1128/JVI.02154-20. Online ahead of print.
A Replication-Defective Influenza Virus Harboring H5 and H7 Hemagglutinins Provides Protection against H5N1 and H7N9 Infection in Mice
Xingui Tian[SUP] 1 [/SUP], Shelby Landreth[SUP] 1 2 [/SUP], Yao Lu[SUP] 1 [/SUP], Kannupriya Pandey[SUP] 1 2 [/SUP], Yan Zhou[SUP] 3 2 4 [/SUP]
Affiliations
Abstract
The recent highly pathogenic avian influenza (HPAI) H5N1 and H7N9 viruses have caused hundreds of human infections with high mortality rates. Although H5N1 and H7N9 viruses have been mainly limited to avian species, there is high potential for these viruses to acquire human-to-human transmission and initiate a pandemic. A highly safe and effective vaccine is needed to protect against a potential H5N1 or H7N9 influenza pandemic. Here, we report the generation and evaluation of two reassortant influenza viruses, PR8-H5-H7[SUB]NA[/SUB] and PR8-H7-H5[SUB]NA[/SUB] These viruses contain six internal segments from A/Puerto Rico/8/1934 (PR8), the HA segment from either A/Alberta/01/2014 (H5N1) [AB14 (H5N1)] or A/British Columbia/01/2015 (H7N9) [BC15 (H7N9)], and a chimeric NA segment with either the BC15 (H7N9) HA gene or the AB14 (H5N1) HA gene flanked by the NA packaging signals of PR8. These viruses expressed both H5 and H7 HAs in infected cells, replicated to high titres when exogenous NA was added to the culture medium in vitro, and were replication-defective and non-virulent when administered intranasally in mice. Moreover, intranasal vaccination with PR8-H5-H7[SUB]NA[/SUB] elicited robust immune responses to both H5 and H7 viruses, conferring complete protection against both AB14 (H5N1) and BC15 (H7N9) challenges in mice. Conversely, vaccination with PR8-H7-H5[SUB]NA[/SUB] only elicited robust immune responses towards the H7 virus, which conferred complete protection against BC15 (H7N9) but not against AB14 (H5N1) in mice. Therefore, PR8-H5-H7[SUB]NA[/SUB] has strong potential to serve as a vaccine candidate against both H5 and H7 subtypes of influenza viruses.Importance Avian influenza H5N1 and H7N9 viruses infected human with high mortality rates. A highly safe and effective vaccine is needed to protect against a potential pandemic. We generated and evaluated two reassortant influenza viruses, PR8-H5-H7[SUB]NA[/SUB] and PR8-H7-H5[SUB]NA[/SUB] as vaccine candidates. Each virus contains one type of HA in segment 4 and the other subtype of HA in segment 6, thus expressing both H5 and H7 subtypes of HA molecule. The viruses' replication is dependent in the addition of exogenous NA in cell culture, and are replication-defective in vivo Vaccination of PR8-H5-H7[SUB]NA[/SUB] virus confers protection to both H5N1 and H7N9 virus challenge; conversely, vaccination of PR8-H7-H5[SUB]NA[/SUB] only provides protection to H7N9 virus challenge. Our data revealed when engineering such virus, the H5 or H7 HA in segment 6 affects the immunogenicity. PR8-H5-H7[SUB]NA[/SUB] has strong potential to serve as a vaccine candidate against both H5 and H7 subtypes of influenza viruses.
. 2020 Nov 11;JVI.02154-20.
doi: 10.1128/JVI.02154-20. Online ahead of print.
A Replication-Defective Influenza Virus Harboring H5 and H7 Hemagglutinins Provides Protection against H5N1 and H7N9 Infection in Mice
Xingui Tian[SUP] 1 [/SUP], Shelby Landreth[SUP] 1 2 [/SUP], Yao Lu[SUP] 1 [/SUP], Kannupriya Pandey[SUP] 1 2 [/SUP], Yan Zhou[SUP] 3 2 4 [/SUP]
Affiliations
- PMID: 33177192
- DOI: 10.1128/JVI.02154-20
Abstract
The recent highly pathogenic avian influenza (HPAI) H5N1 and H7N9 viruses have caused hundreds of human infections with high mortality rates. Although H5N1 and H7N9 viruses have been mainly limited to avian species, there is high potential for these viruses to acquire human-to-human transmission and initiate a pandemic. A highly safe and effective vaccine is needed to protect against a potential H5N1 or H7N9 influenza pandemic. Here, we report the generation and evaluation of two reassortant influenza viruses, PR8-H5-H7[SUB]NA[/SUB] and PR8-H7-H5[SUB]NA[/SUB] These viruses contain six internal segments from A/Puerto Rico/8/1934 (PR8), the HA segment from either A/Alberta/01/2014 (H5N1) [AB14 (H5N1)] or A/British Columbia/01/2015 (H7N9) [BC15 (H7N9)], and a chimeric NA segment with either the BC15 (H7N9) HA gene or the AB14 (H5N1) HA gene flanked by the NA packaging signals of PR8. These viruses expressed both H5 and H7 HAs in infected cells, replicated to high titres when exogenous NA was added to the culture medium in vitro, and were replication-defective and non-virulent when administered intranasally in mice. Moreover, intranasal vaccination with PR8-H5-H7[SUB]NA[/SUB] elicited robust immune responses to both H5 and H7 viruses, conferring complete protection against both AB14 (H5N1) and BC15 (H7N9) challenges in mice. Conversely, vaccination with PR8-H7-H5[SUB]NA[/SUB] only elicited robust immune responses towards the H7 virus, which conferred complete protection against BC15 (H7N9) but not against AB14 (H5N1) in mice. Therefore, PR8-H5-H7[SUB]NA[/SUB] has strong potential to serve as a vaccine candidate against both H5 and H7 subtypes of influenza viruses.Importance Avian influenza H5N1 and H7N9 viruses infected human with high mortality rates. A highly safe and effective vaccine is needed to protect against a potential pandemic. We generated and evaluated two reassortant influenza viruses, PR8-H5-H7[SUB]NA[/SUB] and PR8-H7-H5[SUB]NA[/SUB] as vaccine candidates. Each virus contains one type of HA in segment 4 and the other subtype of HA in segment 6, thus expressing both H5 and H7 subtypes of HA molecule. The viruses' replication is dependent in the addition of exogenous NA in cell culture, and are replication-defective in vivo Vaccination of PR8-H5-H7[SUB]NA[/SUB] virus confers protection to both H5N1 and H7N9 virus challenge; conversely, vaccination of PR8-H7-H5[SUB]NA[/SUB] only provides protection to H7N9 virus challenge. Our data revealed when engineering such virus, the H5 or H7 HA in segment 6 affects the immunogenicity. PR8-H5-H7[SUB]NA[/SUB] has strong potential to serve as a vaccine candidate against both H5 and H7 subtypes of influenza viruses.